Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Array Biopharma Inc | 28 |
| 2 | Schroedinger Inc | 14 |
| 3 | Deciphera Pharmaceuticals LLC | 10 |
| 4 | Foundation Medicine Inc | 9 |
| 5 | Memorial Sloan Kettering Cancer Center | 8 |
| 6 | Emory University | 7 |
| 7 | Loxo Oncology Inc | 6 |
| 8 | Scripps Research Institute | 5 |
| 9 | Yale University | 4 |
| 10 | Acerta Pharma BV | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 169 |
| 2 | A61K | Medicinal preparations | 142 |
| 3 | C07D | Heterocyclic compounds | 89 |
| 4 | C12Q | Measuring/testing involving enzymes | 42 |
| 5 | C07K | Peptides | 35 |
| 6 | C12N | Microorganisms, enzymes | 35 |
| 7 | G01N | Investigating / analysing materials | 28 |
| 8 | C12Y | Enzyme nomenclature (EC numbers) | 14 |
| 9 | Y02A | Climate change adaptation | 9 |
| 10 | C07B | General methods of organic chemistry | 8 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Ajit Jadhav | National Center for Advancing Translational Sciences | 4 |
| 2 | Anton Simeonov | National Center for Advancing Translational Sciences | 4 |
| 3 | Alan J. Kraker | Warde Medical Laboratory | 3 |
| 4 | Bayard D. Clarkson | Memorial Sloan Kettering Cancer Center | 3 |
| 5 | Carleen Klumpp‐Thomas | National Center for Advancing Translational Sciences | 3 |
| 6 | Kelli M. Wilson | National Center for Advancing Translational Sciences | 3 |
| 7 | Kyle R. Brimacombe | National Center for Advancing Translational Sciences | 3 |
| 8 | Matthew D. Hall | National Institutes of Health | 3 |
| 9 | Min Shen | National Institutes of Health | 3 |
| 10 | A Strife | Kettering University | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). | 2002 | 942 | Chronic Lymphocytic Leukemia Research |
| Src activation regulates anoikis in human colon tumor cell lines | 2002 | 213 | Protein Kinase Regulation and GTPase Signaling |
| Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. | 2002 | 161 | Chronic Lymphocytic Leukemia Research |
| Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors | 2000 | 140 | HER2/EGFR in Cancer Research |
| Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. | 1999 | 119 | Microtubule and mitosis dynamics |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and structure classification of PD173955?
Which organizations hold the most patents involving PD173955?
What is the primary research focus of published papers on PD173955?
How has patent activity for PD173955 evolved in recent years?
What are the main patent classification areas associated with PD173955?